Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Selling, General and Administrative Expenses

Last Annual Value

4.92M

3-Year CAGR

8%

5-Year CAGR

192%

10-Year CAGR

71%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Selling, General and Administrative Expenses

ANEB · NASDAQ
CompanySelling, General and Administrative Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
4.92M
-7.3%29.7%N/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
9.23M
-13.8%-13.3%N/A
13.70M
22.7%62.1%N/A
37.72M
-14.0%-1.6%N/A
17.60M
10.7%10.4%2.2%
19.33M
-6.4%7.2%N/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
5.91M
64.1%50.0%N/A
21.15M
N/A15.0%N/A
8.72M
2.3%8.0%13.5%
17.58M
-0.2%-9.8%N/A
16.99M
10.3%8.4%N/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72